. 2018 Jun 1;29(8):2234–2243. doi: 10.1681/ASN.2018020184

Table 3.

C5b9 formation on resting and ADP-activated human microvascular endothelial cells of dermal origin when incubated with follow-up serum samples from patients with hypertension-associated thrombotic microangiopathy

No.	Hb, mmol/L	LDH, U/L	Platelets, ×10⁹/L	Creatinine, μmol/L	C5b9 formation on HMEC-1, % of the control
No.	Hb, mmol/L	LDH, U/L	Platelets, ×10⁹/L	Creatinine, μmol/L	Resting	Activated
Eculizumab treatment
2	7.2	135	199	297	21^a	ND
5	5.5	143	492	ESRD	0^a	0^a
6	6.3	154	298	243	17^a	14^a
9	5.5	179	291	315	0^a	24^a
11	6.8	138	216	132	8^a	29^a
No treatment
8	7.0	239	333	ND	160	231^a
11	6.8	197	174	205	163	293^a
12	6.1	181	232	220	87	171^a
14	7.5	ND	198	98	116	248^a

Hb, hemoglobin; LDH, lactate dehydrogenase; HMEC-1, human microvascular endothelial cells of dermal origin; ND, not determined.

P value <0.05 versus control serum run in parallel.